Kymera Therapeutics KYMR
NASDAQ KYMR
$117.45 +0.17 (+0.14%)
As of: Sep 4, 2026 · 3:59 PM EDT

Kymera Therapeutics (KYMR) EBT Margin Growth (3y) (2022 - 2026)

Analysis

Kymera Therapeutics (KYMR) EBT Margin Growth (3y) (2022 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -484.00
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 132.00
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 6,691.00
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -2,054.00
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 8,006.00
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 9,980.00
8 Royalty Pharma 28.45 Bn 27.61 Bn - -5,319.00
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 31,363.00
10 Kymera Therapeutics 11.52 Bn 10.83 Bn - 14,657.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 14,657.00
Mar 31, 2026 23,435.00
Dec 31, 2025 -317,442.00
Sep 30, 2025 -288,061.00
Jun 30, 2025 -38,296.00
Mar 31, 2025 4,717.00
Dec 31, 2024 -87,009.00
Sep 30, 2024 -178,837.00
Jun 30, 2024 -6,509.00
Mar 31, 2024 -49,230.00
Dec 31, 2023 5,975.00
Sep 30, 2023 -116,141.00
Jun 30, 2023 16,938.00
Mar 31, 2023 -15,033.00
Dec 31, 2022 40,474.00
Sep 30, 2022 77,865.00